Impact of Daily Growth Hormone Adherence on Height Velocity Among Children With Growth Hormone Deficiency (GHD)
Authors' conclusion
Minor improvements in average height velocity were observed in the patient group who were adherent to somatropin therapy, although not statistically significant. Lack of observed significance may be due to small sample sizes, short observation period, a likely heterogenous population in terms of growth hormone prescribing, data bias due to single-center origin, or potential patient misclassification.
Study context
- Population
- Patients aged ≥3 to <16 years with pediatric GHD prescribed somatropin by a pediatric endocrinologist at a US center of excellence, 2015–2020; 70.2% male, 73.5% white, mean age 12.1 (SD 2.8) years174 in height velocity analysis
- Participants
- 181 patients
- Exposure
- Adherent vs nonadherent to daily somatropin
- Adherentn = 108
- Nonadherentn = 66reference
- Outcome
- Annualized height velocity by adherence
- Follow-up
- Within 1 year of treatment start
Methodological detailssingle-centre, real-world
- Single-centre
- Real-world
Main finding
As reported in the abstract
Annualized change in height
Adherent
10.2
mean · SD 5.7 · cm/y
Nonadherent
9.8
mean · SD 7.6
Observational data: associations, not effects.
Original publication
Impact of Daily Growth Hormone Adherence on Height Velocity Among Children With Growth Hormone Deficiency (GHD). Endocr Pract. Published 29 May 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →